HCUP | Jotup

Inflammatix Completes Technical Development for TriVerity™ Acute Infection and Sepsis Test System

Retrieved on:

Mercredi, novembre 15, 2023

SUNNYVALE, Calif., Nov. 15, 2023 /PRNewswire/ -- Inflammatix, Inc., a pioneering molecular diagnostics company, announced today that the company has completed technical development for its TriVerity™ Acute Infection and Sepsis Test System, which includes the Myrna™ Instrument, and for the TriVerity™ Cartridge. TriVerity is intended to be used in emergency department settings in patients with suspected acute infection and sepsis to assess the likelihood of a bacterial infection, a viral infection, and risk of acute decompensation (the need for ICU-level care).

Key Points:

SUNNYVALE, Calif., Nov. 15, 2023 /PRNewswire/ -- Inflammatix, Inc., a pioneering molecular diagnostics company, announced today that the company has completed technical development for its TriVerity™ Acute Infection and Sepsis Test System, which includes the Myrna™ Instrument, and for the TriVerity™ Cartridge.
TriVerity is intended to be used in emergency department settings in patients with suspected acute infection and sepsis to assess the likelihood of a bacterial infection, a viral infection, and risk of acute decompensation (the need for ICU-level care).
The TriVerity Acute Infection and Sepsis Test, Inflammatix's lead product, incorporates a panel of 29 mRNAs to "read" the body's immune response and thus aid in the diagnosis of patients with suspected acute infection and sepsis.
The TriVerity Acute Infection and Sepsis Test System is a product in development, is not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.

Gunshot Detection Systems Market worth $1,443 million by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Lundi, octobre 16, 2023

A gunshot detection system can be installed indoors or outdoors and provides coverage in the event of an active shooting attack.

Key Points:

A gunshot detection system can be installed indoors or outdoors and provides coverage in the event of an active shooting attack.
Based on Installation, Soldier Mounted Systems segment is projected to lead the Gunshot Detection Systems industry during the forecast period.
Militaries of several countries have invested in systems such as EARS (QinetiQ) and Pearl (ACOEM Group), which are a few types of wearable gunshot detection systems.
The Gunshot Detection Systems market industry has been studied in North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Gunshot Detection Systems Market worth $1,443 million by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Lundi, octobre 16, 2023

A gunshot detection system can be installed indoors or outdoors and provides coverage in the event of an active shooting attack.

Key Points:

A gunshot detection system can be installed indoors or outdoors and provides coverage in the event of an active shooting attack.
Based on Installation, Soldier Mounted Systems segment is projected to lead the Gunshot Detection Systems industry during the forecast period.
Militaries of several countries have invested in systems such as EARS (QinetiQ) and Pearl (ACOEM Group), which are a few types of wearable gunshot detection systems.
The Gunshot Detection Systems market industry has been studied in North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease

Retrieved on:

Lundi, juin 6, 2022

Oxygen, Goal, Sickle cell disease, RPD, Acute chest syndrome, China Biologic Products, National Heart, Lung, and Blood Institute, Pain, Blood, COVID-19, Food and Drug Administration, European Medicines Agency, HBS, Tissue, Capillary, U.S. Securities and Exchange Commission, Volatile organic compound, Stroke, Food, Pharmacokinetics, Awareness, Hemolytic anemia, Degenerative disease, Securities Exchange Act of 1934, Lung, Securities Act of 1933, Pharmakon—Danish College of Pharmacy Practice, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GBT, Polymerization, Registry, Roche, Government, Cell adhesion, Patient, Compliance, Private Securities Litigation Reform Act, Research, Drug Quality and Security Act, HCUP, United, Disease, Maintenance, Center, FDA, SCD, GLOBE, NASDAQ, SAN, P-selectin, Safety, Pharmaceutical industry, Voxelotor

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug and rare pediatric disease designations for inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease (SCD). Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to evaluate its potential to reduce the occurrence of vaso-occlusive crises (VOCs) and readmissions due to VOCs in patients with SCD. GBT601, a next generation sickle hemoglobin (HbS) polymerization inhibitor, is being studied in a restarted Phase 1 clinical trial and is expected to advance into the Phase 2 portion of a Phase 2/3 trial by mid-year. “The FDA’s orphan drug and rare pediatric disease designations for both inclacumab and GBT601 are an acknowledgment of the critical and ongoing unmet need in sickle cell disease and the potential of GBT’s innovative pipeline of investigational medicines,” said Kim Smith-Whitley, M.D., executive vice president and head of research and development at GBT. “We believe that both inclacumab and GBT601 have the potential to be best-in-class therapeutic options for the treatment of this devasting disease. We are excited to continue these clinical development programs to make progress on our goal of transforming sickle cell disease into a well-managed condition via multiple therapeutic approaches.”

Key Points:

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug and rare pediatric disease designations for inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease (SCD).
We believe that both inclacumab and GBT601 have the potential to be best-in-class therapeutic options for the treatment of this devasting disease.
Inclacumab selectively targets P-selectin, a protein that mediates cell adhesion and is clinically validated to reduce pain crises.
The second registrational trial, GBT2104-132 ( NCT04927247 ), is evaluating the effect of a single dose of inclacumab on hospital readmission rates.

United States Hospital Facilities Market Analysis Report 2022-2030 Patient Service (Inpatient, Outpatient), & Service Type (Acute Care, Cardiovascular) - ResearchAndMarkets.com

Retrieved on:

Jeudi, avril 14, 2022

The "U.S. Hospital Facilities Market Size, Share & Trends Analysis Report by Patient Service (Inpatient, Outpatient), by Service Type (Acute Care, Cardiovascular), by Facility Type, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "U.S. Hospital Facilities Market Size, Share & Trends Analysis Report by Patient Service (Inpatient, Outpatient), by Service Type (Acute Care, Cardiovascular), by Facility Type, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
According to the American Hospital Association (AHA), there were more than 36.2 million patients admitted to U.S. hospitals, in 2021.
Hospitals provide treatment for a variety of indications, including neurology, cardiology, infectious disorders, gastrointestinal diseases, and psychiatric disorders.
The cardiovascular service type segment dominated the market in 2021 due to changing & sedentary lifestyles and the increased geriatric & obese population.